NCT07906054
Ultra-high-performance Positron Emission Tomography (PET) of Synaptic Density, Reactive Astrogliosis and Tau in Alzheimer's Disease
StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)
At risk: Primary endpoint(s) modified.
See at-risk trials from Universitaire Ziekenhuizen KU Leuven
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Start date pushed from Oct 2026 to Dec 2026
- Study completion moved earlier from Oct 2029 to Jun 2029
- Notable Primary endpoint(s) modified
- Secondary endpoints revised (3)
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
The correlation between tau, synaptic density and reactive astrogliosis
Timeframe: Baseline
Changes in synaptic density, tau and reactive astrolgiosis between AD patients, controls and centenarians
Timeframe: Baseline
Secondary (3)
Correlation of synaptic density, tau and reactive astrogliosis with diffusion MRI
Correlation of synaptic density, tau and reactive astrogliosis with blood-based biomarkers
Correlation of synaptic density, tau and reactive astrogliosis with cognitive performance
Arms and interventions
Patients with AD
Healthy control participants
Centenarians
Other: 18F-SMBT-1 PET, 18F-SynVesT-1 PET, 18F-MK-6240 PET
Sites
1 site in 1 country
- University Hospitals LeuvenLeuven, Vlaams-Brabant, Belgium